VALANX Biotech Appoints New Chief Scientific Officer
VALANX Biotech has appointed Klaus Orlinger, PhD, as its new Chief Scientific Officer, bolstering its leadership team as the company progresses its first antibody drug conjugate to candidate selection phase.
Klaus Orlinger brings over 15 years of industry experience in developing oncology and infectious disease drug candidates to the role.
His appointment will drive the development of VALANX' GoldenSite platform to advance the development of best-in-class therapeutic protein conjugates.
Author's summary: VALANX Biotech appoints Klaus Orlinger as CSO.